Welcome to our dedicated page for Ventas SEC filings (Ticker: VTR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ventas, Inc. (NYSE: VTR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a healthcare-focused S&P 500 real estate investment trust. Through these filings, investors can review how Ventas reports on its portfolio of approximately 1,400 properties in North America and the United Kingdom, including senior housing communities, outpatient medical buildings, research centers and other healthcare facilities.
Current and historical Forms 8-K offer detailed information about material events affecting Ventas and its subsidiaries. Recent 8-K filings describe items such as the pricing and issuance of senior notes by Ventas Realty, Limited Partnership, amendments to unsecured term loan facilities guaranteed by Ventas, and announcements of quarterly results. These documents help readers understand the company’s capital structure, borrowing arrangements and operating performance disclosures.
Other SEC filings, such as annual reports on Form 10-K and quarterly reports on Form 10-Q, provide broader context on Ventas’s business, risk factors, REIT structure and segment performance. For a healthcare REIT like Ventas, these reports typically include discussions of its senior housing operating portfolio, outpatient medical and research assets, and the demographic and regulatory environment relevant to its properties.
Investors can also use SEC filings to track matters such as dividend practices, debt covenants, and the terms of public offerings or credit agreements. On Stock Titan, AI-powered tools summarize lengthy filings, highlight key sections and surface important changes across reporting periods, helping users interpret complex documents more efficiently. Real-time updates from the SEC’s EDGAR system mean that new Ventas filings, including 10-K, 10-Q, 8-K and related exhibits, are available promptly, while Form 4 and other ownership reports can be consulted to analyze insider transactions and equity-based compensation activity associated with VTR.
Ventas, Inc. is an S&P 500 healthcare REIT focused on senior housing, outpatient medical buildings, research centers, hospitals and other healthcare assets in North America and the U.K. As of December 31, 2025, it owned or had investments in 1,409 properties, including 1,374 segment properties.
The company operates through three main segments: senior housing operating (SHOP), outpatient medical and research (&R) and triple-net leased (NNN). For 2025, total NOI was $2.39 billion, with SHOP contributing $1.18 billion (49.4%), &R $590 million (24.7%) and NNN $588 million (24.6%). Non-segment activities added $30.7 million.
Ventas highlights concentration risk with key managers and tenants such as Atria, Sunrise, Le Groupe Maurice, Brookdale, Kindred and Ardent, and outlines extensive regulatory, reimbursement, macroeconomic, labor and REIT qualification risks. At June 30, 2025, its public float was valued at $28.6 billion, and 474,965,224 common shares were outstanding as of February 3, 2026.
Ventas, Inc. reported strong fourth quarter and full-year 2025 results driven by its senior housing portfolio and announced an 8% dividend increase. In Q4 2025, net income attributable to common stockholders was $0.15 per share, while Nareit FFO was $0.91 and Normalized FFO was $0.89 per share, up 10% from 2024. For 2025, net income per share rose to $0.54, with Nareit FFO of $3.50 and Normalized FFO of $3.48 per share, reflecting 11% and 9% growth, respectively. Same-store Cash NOI grew 8% for the year, with the SHOP segment exceeding 15% growth, supported by higher occupancy and rate gains. Ventas completed $2.5 billion of senior housing investments in 2025, raised $3.2 billion of equity, and ended the year with $5.3 billion of liquidity and Net Debt-to-Further Adjusted EBITDA of 5.2x. The quarterly dividend was raised to $0.52 per share, payable April 16, 2026. For 2026, the company guides to midpoints of $0.57 in net income per share, $3.68 in Nareit FFO per share, and $3.83 in Normalized FFO per share, implying 8% year-over-year Normalized FFO growth on a comparable basis.
Ventas, Inc. executive Carey S. Roberts, EVP and General Counsel, reported routine tax-related share withholdings on February 1, 2026. Three Form 4 transactions, all coded "F", reflect common shares withheld to pay taxes upon vesting of restricted stock units granted under the Ventas, Inc. 2022 Incentive Plan.
The transactions covered 2,239, 2,245, and 2,270 shares of common stock at a reference price of $77.67 per share, with ownership remaining directly held. After these withholdings, Roberts continued to beneficially own over one hundred thousand shares of Ventas common stock.
Ventas, Inc. executive vice president and CFO Robert F. Probst reported routine share withholdings related to restricted stock unit vesting on February 1, 2026. A total of 3,244, 3,252, and 3,704 shares of common stock were withheld at a price of $77.67 per share to cover taxes on RSUs granted in 2023, 2024, and 2025 under the Ventas, Inc. 2022 Incentive Plan. After these tax-withholding transactions, he beneficially owned 125,959 shares of Ventas common stock directly.
Ventas, Inc. executive James Justin Hutchens reported share withholding transactions tied to restricted stock vesting. On February 1, 2026, a total of 2,894, 3,046, and 3,643 shares of common stock were withheld to pay taxes on vested restricted stock units granted in 2023, 2024, and 2025 under the Ventas, Inc. 2022 Incentive Plan, at a reference price of $77.67 per share. After these tax withholdings, Hutchens directly beneficially owned 157,466 shares of Ventas common stock.
Ventas, Inc. Chairman and CEO Debra A. Cafaro reported several equity transactions in early February 2026. On February 1, 2026, shares of common stock (7,668, 7,686 and 8,407) were withheld at $77.67 per share to cover taxes on vested restricted stock units from grants made in 2023, 2024 and 2025.
On February 2, 2026, she exercised 10,322 stock options at an exercise price of $73.71 per share, from options that were fully vested and scheduled to expire on August 3, 2026. The same day, 10,322 shares of common stock were sold at a weighted average price of $77.6599 per share under a Rule 10b5-1 trading plan established on March 28, 2024.
After these transactions, Cafaro directly beneficially owned 1,114,034 shares of Ventas common stock and held 10,322 unexercised stock options.
Ventas, Inc. executive Peter J. Bulgarelli reported tax‑related share withholdings tied to equity vesting. On February 1, 2026, three Form 4 transactions (code F) show a total of 7,058 shares of common stock withheld at $77.67 per share to cover taxes on restricted stock units granted in 2023, 2024, and 2025 under the Ventas, Inc. 2022 Incentive Plan. After these withholding events, he directly held 97,754 shares of Ventas common stock.
Ventas, Inc. insider Debra Cafaro has filed a Form 144 to sell 10,322 shares of Ventas common stock. The shares are to be sold through Merrill Lynch on the NYSE, with an aggregate market value of $801,605.71 and 469,732,824 Ventas shares outstanding.
The 10,322 shares come from a broker-assisted exercise of employee stock options on 02/02/2026, with acquisition and payment occurring the same day. Over the prior three months, Cafaro reported multiple Ventas stock sales totaling several hundred thousand shares and generating tens of millions of dollars in gross proceeds.
JPMorgan Chase & Co. has filed a Schedule 13G showing a significant ownership position in Ventas, Inc. common stock. As of 12/31/2025, JPMorgan reports beneficial ownership of 28,174,629 Ventas shares, representing 5.9% of the outstanding common stock.
The filing states JPMorgan has sole voting power over 22,685,575 shares and shared voting power over 1,573,364 shares, with sole dispositive power over 26,876,054 shares and shared dispositive power over 1,297,916 shares. JPMorgan certifies the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Ventas.
Ventas, Inc. director Maurice S. Smith reported routine share accruals tied to dividends. On January 15, 2026, he acquired 57.483 units of common stock under the Ventas Non-Employee Directors' Cash Compensation Deferral Plan and 68.063 units under the Non-Employee Directors' Equity Award Deferral Program, both credited as dividend equivalents at a reference price of $76.92 per share.
These units are payable solely in Ventas common stock and are subject to his deferral elections and the governing plans. Following the reported transactions, Smith beneficially owns 28,092.352 shares of Ventas common stock directly.